Company intelligence / Profile preview

Pharosgen

South Korea

Ownership: Private
Development stage: Other

Overview

Pharosgen is advancing two lead programs: MPD-1 (PGP2113), a peptide-drug conjugate in Phase 1 for advanced solid tumors characterized by PTEN loss and KRAS mutation, and TNT-ADC, an antibody-drug conjugate targeting cancer and new vascular endothelial cells. MPD-1 uniquely combines with serum albumin for targeted delivery and utilizes a prodrug activated by caspase-3/7 to enable bystander killing effect, aiming to overcome tumor heterogeneity.

Therapeutic areas: Oncology
Modalities: Peptide-drug conjugateAntibody-drug conjugate
Industry: Biotech

Drug pipeline

2 assets

MPD-1

1 more asset in the full pipeline.

Request access →

Partnerships

Seoul National University College of PharmacyUlsan National UniversityKorea Institute of Science and Technology (KIST)

Beyond the preview

Go deeper on Pharosgen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharosgen.

Explore the full profile